Skip to main content

Has blinatumomab been funded by Pharmac for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukaemia; and if not, is it under consideration for funding?

Answered Question 18921 (2026)
Question published
Reply lodged
Bookmark

Asked by

Ayesha Verrall

List MP · Labour Party

Question

  • Has blinatumomab been funded by Pharmac for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukaemia; and if not, is it under consideration for funding?

Answered by

Hon David Seymour

Member for Epsom · ACT Party · Associate Minister of Health

Answer

I am advised by Pharmac that an application for blinatumomab for this indication has been received and is currently awaiting clinical advice. I refer the Member to the following link for more information: https://connect.pharmac.govt.nz/apptracker/s/application-public/a10OZ000007O2Ss/p002198